A Multi-Centre, Randomized, Double Blind Cross-Over Study to Assess the Non-Inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

Trial Profile

A Multi-Centre, Randomized, Double Blind Cross-Over Study to Assess the Non-Inferiority of GW685698X 200mcg Once Daily and 100mcg Twice Daily in Adult and Adolescent Patients With Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Sep 2010 Results presented at the European Respiratory Society congress, according to a GSK media release.
    • 03 Dec 2008 Status changed from recruiting to active, no longer recruiting.
    • 26 Nov 2008 Planned number of patients changed from 750 to 375.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top